Bettina Wingelhofer
Vienna, 1210, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target.
Journal: Leukemia
Published: June 28, 2023
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.
Journal: Molecular cancer
Published: March 23, 2023
Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Journal: Cancer cell
Published: July 08, 2022
HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block.
Journal: Oncogene
Published: January 04, 2022
STAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms.
Journal: Cancers
Published: April 03, 2020
STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway.
Journal: Oncogene
Published: February 19, 2020
Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia.
Journal: Frontiers in oncology
Published: April 05, 2019
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.
Journal: Haematologica
Published: January 18, 2019
The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease.
Journal: Cancer cell
Published: March 15, 2018
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.
Journal: Expert opinion on therapeutic targets
Published: November 18, 2017
Last Updated: 09/26/2026